Acyclovir

Generic Name: Acyclovir

Brand Names: Sitavig, Xerese, Zovirax

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₁N_₅O_₃

CAS Number: 59277-89-3

Unique Ingredient Identifier: X4HES1O11F

Background: Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old.

Acyclovir was granted FDA approval on 29 March 1982.

Indication: An acyclovir topical cream is indicated to treat recurrent herpes labialis in immunocompetent patients 12 years and older. Acyclovir oral tablets, capsules, and suspensions are indicated to treat herpes zoster, genital herpes, and chickenpox. An acyclovir topical ointment is indicated to treat initial genital herpes and limited non-life-threatening mucocutaneous herpes simplex in immunocompromised patients. An acyclovir cream with hydrocortisone is indicated to treat recurrent herpes labialis, and shortening lesion healing time in patients 6 years and older. An acyclovir buccal tablet is indicated for the treatment of recurrent herpes labialis. An acyclovir ophthalmic ointment is indicated to treat acute herpetic keratitis.

Associated Conditions: Bell's Palsy, Chickenpox, Cytomegalovirus (CMV) Infections, Herpes Simplex Infections, Herpes Zoster, Herpes simplex encephalitis, Herpes simplex of the oral-labial, Herpes simplex type I reactivation, Recurrent Genital Herpes (RGH), Recurrent Herpes Labialis, VZV re-activation, Acute Genital herpes, Acute Herpes labialis, Acute Herpetic keratitis, Severe Genital herpes

Clinical Trials

Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

Phase 4

Completed

Conditions: Genital Herpes

Interventions: Drug: acyclovir
Drug: valacyclovir

First Posted Date: 2006-08-09

Last Posted Date: 2021-11-18

Lead Sponsor: University of Washington

Target Recruit Count: 31

Registration Number: NCT00362297

Locations: 🇺🇸
University of Washington Virology Research Clinic, Seattle, Washington, United States

Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)

Phase 3

Completed

Conditions: Cytomegalovirus
Bone Marrow Transplantation

Interventions: Drug: Acyclovir
Drug: Valganciclovir

First Posted Date: 2006-05-25

Last Posted Date: 2015-04-21

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 40

Registration Number: NCT00330018

Locations: 🇮🇱
Hadassah Medical Organization,, Jerusalem, Israel

Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon

Phase 2

Completed

Conditions: HIV-1 and HSV-2 Coinfection
HIV Infections

Interventions: Drug: Acyclovir

First Posted Date: 2005-09-21

Last Posted Date: 2011-12-16

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00209313

Locations: 🇨🇲
Hospital Central, Yaounde, Cameroon

Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

Phase 3

Completed

Conditions: VZV Infection After Bone Marrow Transplantation

First Posted Date: 2005-09-21

Last Posted Date: 2007-12-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 120

Registration Number: NCT00209352

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission

Phase 3

Completed

Conditions: HIV Infection
Herpes Simplex, Genital
Sexually Transmitted Diseases

Interventions: Drug: Generic acyclovir
Drug: Placebo

First Posted Date: 2005-09-19

Last Posted Date: 2018-10-12

Lead Sponsor: University of Washington

Target Recruit Count: 3408

Registration Number: NCT00194519

Locations: 🇺🇬
Mulago Hospital - IDI, Kampala, Uganda
🇷🇼
Projet San Francisco-Emory University, Kigali, Rwanda
🇰🇪
University of Nairobi, Nairobi, Kenya

and more 9 locations

Episodic Acyclovir Therapy for Genital Ulcers

Phase 2

Completed

Conditions: HIV Infections
Ulcer
Herpes Simplex

First Posted Date: 2005-09-14

Last Posted Date: 2012-09-11

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 613

Registration Number: NCT00164424

Locations: 🇿🇦
Eloff Street Clinic, Johannesburg, Gauteng, South Africa
🇿🇦
Green Door, Alexandra Health Centre, Johannesburg, Gauteng, South Africa

Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212)

Phase 2

Completed

Conditions: Ulcer
Herpes Genitalis

First Posted Date: 2005-09-12

Last Posted Date: 2008-12-30

Lead Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Target Recruit Count: 449

Registration Number: NCT00158483

Locations: 🇬🇭
WAPTCAS, Accra, Ghana
🇬🇭
Kumasi Hospital, Service d'infectiologie, Kumasi, Ghana
🇨🇫
Centre MST/SIDA, Bangui, Central African Republic

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

Phase 1

Completed

Conditions: Kidney Transplantation
Kidney Disease

Interventions: Drug: Alemtuzumab
Drug: Sirolimus
Drug: Tacrolimus
Procedure: Kidney transplant
Drug: Methylprednisolone (or equivalent)
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Trimethoprim (TMP)/Sulfa (Bactrim, Septra)
Drug: Valgancyclovir
Drug: Acyclovir
Drug: Pentamidine
Drug: Clotrimazole
Drug: Nystatin

First Posted Date: 2004-03-02

Last Posted Date: 2018-06-29

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 10

Registration Number: NCT00078559

Locations: 🇺🇸
University of Wisconsin - Department of Medicine, Madison, Wisconsin, United States

A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes

Phase 3

Completed

Conditions: HIV Infections
Herpes Genitalis
HIV Seronegativity

Interventions: Drug: Acyclovir
Drug: Acyclovir placebo

First Posted Date: 2004-01-16

Last Posted Date: 2010-12-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 3682

Registration Number: NCT00076232

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸
San Francisco Department of Public Health, AIDS Office, Research Section, San Francisco, California, United States
🇺🇸
New York Blood Center, New York City, New York, United States

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Acute Undifferentiated Leukemia
B-cell Adult Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphoblastic Leukemia
L1 Adult Acute Lymphoblastic Leukemia
L1 Childhood Acute Lymphoblastic Leukemia
L2 Adult Acute Lymphoblastic Leukemia
L2 Childhood Acute Lymphoblastic Leukemia
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia

Interventions: Drug: allopurinol
Drug: cyclophosphamide
Drug: daunorubicin hydrochloride
Drug: vincristine sulfate
Drug: dexamethasone
Drug: asparaginase
Biological: filgrastim
Drug: imatinib mesylate
Drug: methotrexate
Drug: cytarabine
Drug: trimethoprim-sulfamethoxazole
Drug: mercaptopurine
Drug: leucovorin calcium
Biological: alemtuzumab
Drug: acyclovir
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-06-06

Last Posted Date: 2022-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 302

Registration Number: NCT00061945

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy